[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100556601":3},{"organization":4,"armGroups":7,"interventions":24,"overallOfficials":40,"centralContacts":45,"locations":51,"responsibleParty":161,"collaborators":165,"id":168,"slug":39,"hasResults":169,"nctId":170,"briefTitle":171,"officialTitle":172,"acronym":39,"eligibilityCriteria":173,"healthyVolunteers":169,"sex":174,"minAge":175,"maxAge":39,"enrollmentInfo":176,"targetDuration":39,"studyType":179,"phases":180,"briefSummary":182,"conditions":183,"keywords":185,"overallStatus":53,"whyStopped":39,"lastUpdateSubmitDate":190,"lastUpdatePostDateStruct":191,"startDateStruct":194,"completionDateStruct":196,"leadSponsor":198,"locationsCount":199},{"fullName":5,"class":6},"University of California, San Francisco","OTHER",[8,14,18],{"label":9,"type":10,"description":11,"interventionNames":12},"Ranolazine low dose","EXPERIMENTAL","Participants receive Ranolazine 500mg orally twice daily for 24 weeks.",[13],"Drug: Ranolazine",{"label":15,"type":10,"description":16,"interventionNames":17},"Ranolazine high dose","Participants receive Ranolazine 1000mg orally twice daily for 24 weeks.",[13],{"label":19,"type":20,"description":21,"interventionNames":22},"Placebo","PLACEBO_COMPARATOR","Participants receive Ranolazine placebo orally twice daily for 24 weeks.",[23],"Drug: Placebo",[25,32,36],{"type":26,"name":27,"description":28,"armGroupLabels":29,"otherNames":30},"DRUG","Ranolazine","500mg twice daily",[9],[31],"Ranexa",{"type":26,"name":27,"description":33,"armGroupLabels":34,"otherNames":35},"1000 mg twice daily",[15],[31],{"type":26,"name":19,"description":37,"armGroupLabels":38,"otherNames":39},"Ranolazine placebo twice daily",[19],null,[41],{"name":42,"affiliation":43,"role":44},"Jeffrey Statland, MD","University of Kansas Medical Center","PRINCIPAL_INVESTIGATOR",[46],{"name":47,"role":48,"phone":49,"phoneExt":39,"email":50},"Katie Lillig, BS","CONTACT","913-945-9932","Kjennens2@kumc.edu",[52,73,90,106,125,142],{"facility":5,"status":53,"city":54,"state":55,"zip":56,"country":57,"cosmosGeoPoint":58,"geoPoint":63,"contacts":64},"RECRUITING","San Francisco","California","94143","United States",{"type":59,"coordinates":60},"Point",[61,62],-122.41942,37.77493,{"lat":62,"lon":61},[65,69,71],{"name":66,"role":48,"phone":67,"phoneExt":39,"email":68},"Michael Han","415-353-7381","Michael.Han@ucsf.edu",{"name":39,"role":48,"phone":39,"phoneExt":39,"email":70},"Neuromuscular.Research@ucsf.edu",{"name":72,"role":44,"phone":39,"phoneExt":39,"email":39},"Swathy Chandrashekhar, MD",{"facility":74,"status":53,"city":75,"state":76,"zip":77,"country":57,"cosmosGeoPoint":78,"geoPoint":82,"contacts":83},"Mayo Clinic Florida","Jacksonville","Florida","32224",{"type":59,"coordinates":79},[80,81],-81.65565,30.33218,{"lat":81,"lon":80},[84,88],{"name":85,"role":48,"phone":86,"phoneExt":39,"email":87},"Huy B. Tran","904-953-4503","Tran.Huy1@mayo.edu",{"name":89,"role":44,"phone":39,"phoneExt":39,"email":39},"Bjorn E Oskarsson, MD",{"facility":43,"status":53,"city":91,"state":92,"zip":93,"country":57,"cosmosGeoPoint":94,"geoPoint":98,"contacts":99},"Fairway","Kansas","66205",{"type":59,"coordinates":95},[96,97],-94.6319,39.02223,{"lat":97,"lon":96},[100,104,105],{"name":101,"role":48,"phone":102,"phoneExt":39,"email":103},"Nick Staudenmier, BS","913-945-9922","nstaudenmier@kumc.edu",{"name":47,"role":48,"phone":49,"phoneExt":39,"email":50},{"name":42,"role":44,"phone":39,"phoneExt":39,"email":39},{"facility":107,"status":53,"city":108,"state":92,"zip":109,"country":57,"cosmosGeoPoint":110,"geoPoint":114,"contacts":115},"University of Kansas Medical Center: Wichita","Wichita","67214",{"type":59,"coordinates":111},[112,113],-97.33754,37.69224,{"lat":113,"lon":112},[116,120,123],{"name":117,"role":48,"phone":118,"phoneExt":39,"email":119},"KUMC CTSU Wichita","316-293-1833","clinicaltrialunit@kumc.edu",{"name":121,"role":48,"phone":39,"phoneExt":39,"email":122},"Hannah Hancock","hhancock@kumc.edu",{"name":124,"role":44,"phone":39,"phoneExt":39,"email":39},"Matthew Byerly, MD",{"facility":126,"status":53,"city":127,"state":128,"zip":129,"country":57,"cosmosGeoPoint":130,"geoPoint":134,"contacts":135},"University of Missouri Health Care","Columbia","Missouri","65212",{"type":59,"coordinates":131},[132,133],-92.33407,38.95171,{"lat":133,"lon":132},[136,140],{"name":137,"role":48,"phone":138,"phoneExt":39,"email":139},"Amanda Heider","573-884-6852","ahmc4@umsystem.edu",{"name":141,"role":44,"phone":39,"phoneExt":39,"email":39},"William D Arnold, MD",{"facility":143,"status":53,"city":144,"state":145,"zip":146,"country":57,"cosmosGeoPoint":147,"geoPoint":151,"contacts":152},"The Ohio State University","Columbus","Ohio","43210",{"type":59,"coordinates":148},[149,150],-82.99879,39.96118,{"lat":150,"lon":149},[153,156,159],{"name":154,"role":48,"phone":39,"phoneExt":39,"email":155},"Atchayah Balakrishna","Atchayah.Balakrishna@osumc.edu",{"name":157,"role":48,"phone":39,"phoneExt":39,"email":158},"Kaneshia Hives","Kaneshia.Hives@osumc.edu",{"name":160,"role":44,"phone":39,"phoneExt":39,"email":39},"Sarah Heintzman, CNP",{"type":162,"investigatorFullName":163,"investigatorTitle":164,"investigatorAffiliation":5,"oldNameTitle":39,"oldOrganization":39},"SPONSOR_INVESTIGATOR","Swathy Chandrashekhar, MBBS","Principal Investigator",[166],{"name":167,"class":6},"ALS Association","100556601",false,"NCT06527222","A Study of Ranolazine in ALS","Ranolazine in ALS: Safety, and Effect on Cramps, Function and Quality of Life.","Inclusion Criteria:\n\n* 18 years or older\n* Diagnosed with clinically definite, possible, probably, or lab-supported probable ALS per revised El Escorial criteria\n* Breathing assessment called forced vital capacity (FVC) greater than or equal to 50%.\n* Able to swallow pills at the start of the study and expected to for the length of the study.\n* If on ALS modifying medications must be on a stable dose at least 30 days.\n* Experiencing 4 or more cramps per week during a 2-week screening period.\n\nExclusion Criteria:\n\n* Disease duration \\\u003C 5 years\n* Tracheostomy invasive ventilation, or noninvasive ventilation of more than 12 hours\u002Fday\n* Pregnant or lactating, adults unable to consent, and prisoners\n* Taking ranolazine or investigational drug or has received an investigational drug within 30 days (or 5 half-lives for drugs, whichever is longer) prior to screening\n* Medically uncontrolled comorbidities (heart, liver, kidney disease)\n* Baseline QTc interval prolongation \\>450 ms for men\u002F \\>470 ms for women, history of long QT syndrome, or medications which prolong the QT interval\n* Participation in an experimental drug trial less than 30 days before screening\n* Patients have to be on a stable dosage of any medications used to treat muscle cramps for ≥30 days or have been off these medications ≥30 days prior to randomization.","ALL","18 Years",{"count":177,"type":178},72,"ESTIMATED","INTERVENTIONAL",[181],"PHASE2","The purpose of this study is to evaluate safety, effect on cramps, function and quality of life of ranolazine versus placebo for the treatment of ALS.",[184],"Amyotrophic Lateral Sclerosis",[186,187,188,189],"ALS","Motor Neuron Disease","Lou Gehrig's Disease","Placebo-Controlled","2026-06-04",{"date":192,"type":193},"2026-06-08","ACTUAL",{"date":195,"type":193},"2025-04-29",{"date":197,"type":178},"2028-07",{"name":163,"class":6},6]